Sinopep-Allsino Bio Pharmaceutical

Sinopep is a prominent Chinese biopharmaceutical company specializing in the large-scale synthesis and manufacturing of complex peptide and small molecule drugs. The company operates a dual business model, serving as a high-end CDMO for global pharmaceutical partners while developing its own internal pipeline of generic and innovative therapeutics. Sinopep is particularly recognized for its leadership in the GLP-1 market, providing APIs and finished dosages for blockbuster treatments like semaglutide and liraglutide. Their technical expertise extends to advanced oligonucleotide synthesis and difficult-to-manufacture chiral small molecules. Headquartered in Hangzhou with major manufacturing facilities in Lianyungang, the company is listed on the Shanghai Stock Exchange STAR Market.